Flash Mob Study With Regard to Travel Willingness Among Patients With Cancer

July 3, 2023 updated by: University Medical Center Groningen

Flashmobstudie Landelijke Meting Reisbereidheid Medisch Oncologische Zorg

This is a cross-sectional study in the form of a flash mob study, in which an inventory will be made on 13 and 14 March 2023 of the willingness to travel of oncology patients in the participating hospitals. Patients who have an appointment with an internist-oncologist or oncology specialist nurse at the outpatient clinic or by telephone and patients who come to day treatment unit for medical oncology are asked to participate. Willingness to travel is examined by means of a survey, in which a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

5000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
      • Groningen, Netherlands, 9713 GZ
        • University Medical Center Groningen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Medical Oncology patients who have an (call) appointment with our medical oncology outpatient clinic and/or day treatment unit on 13 or 14 march 2023.

Description

Inclusion criteria:

  • Medical oncology patients with an appointment in the out-patient clinic or day treatment unit on 13 or 14 march 2023
  • Medical oncology patients with an (video) call appointment in the out-patient clinic on 13 or 14 march 2023

Exclusion criteria:

  • Patients in the inpatients oncology unit
  • Medical oncology patients with no appointment on 13 or 14 march 2023

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cohort: medical oncology patients in the out-patient clinic or treatment unit on 13 or 14 march 2023
No interventions.
Other: Survey about travel willingness regarding cancer treatment and follow-up
No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Travel willingness
Time Frame: 1 day
How far is the oncological patient willing to travel for his/her systemic treatment or follow-up?
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Facilitating and inhibiting factors for willingness to travel
Time Frame: 1 day
What are facilitating and inhibiting factors in patients' willingness to travel?
1 day
Which patient characteristics are associated with willingness to travel?
Time Frame: 1 day
Which patient characteristics are associated with willingness to travel? (age, type of cancer, curative/palliative treatment, distance to nearest hospital)
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Medical Center Groningen

Investigators

  • Principal Investigator: An KL Reyners, MD, PhD, University Medical Center Groningen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 13, 2023

Primary Completion (Actual)

May 1, 2023

Study Completion (Actual)

May 1, 2023

Study Registration Dates

First Submitted

March 20, 2023

First Submitted That Met QC Criteria

July 3, 2023

First Posted (Actual)

July 11, 2023

Study Record Updates

Last Update Posted (Actual)

July 11, 2023

Last Update Submitted That Met QC Criteria

July 3, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 15954

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on Survey about travel willingness regarding cancer treatment and follow-up

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe